Bioequivalence and pharmacokinetic comparison of a single 200-mg dose of meclofenoxate hydrochloride capsule and tablet formulations in healthy chinese adult male volunteers: a randomized sequence, open-label, two-period crossover study

Clinical Therapeutics

Volumn 30, Issue 9, 2008, Pages 1651-1657

  Zou, Jian Jun ^a   Ji, Hong Jian ^b   Wu, Ding Wei ^c   Yao, Jing ^d   Hu, Qin ^b   Xiao, Da Wei ^a   Wang, Guang Ji ^d  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c Zhejiang XianJu Pharmaceutical Technology Co LTD   (China)

^d CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

bioavailability; bioequivalence; high performance; human plasma; liquid chromatography; meclofenoxate hydrochloride; pharmacokinetics

Indexed keywords

4 CHLOROPHENOXYACETIC ACID; CHLOROPHENOXYACETIC ACID; DRUG METABOLITE; MECLOFENOXATE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHINA; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DETERMINATION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG TOLERABILITY; EXCITEMENT; FOOD AND DRUG ADMINISTRATION; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INSOMNIA; LASSITUDE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL AVAILABILITY; CAPSULES; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; DRUG TOLERANCE; HUMANS; MALE; MECLOFENOXATE; NONTHERAPEUTIC HUMAN EXPERIMENTATION; NOOTROPIC AGENTS; REFERENCE VALUES; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 53049106926     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.09.013     Document Type: Article

References (23)

1. Gedye J.L., Exton-Smith A.N., and Wedgwood J. A method for measuring mental performance in the elderly and its use in a pilot clinical trial of meclofenoxate in organic dementia (preliminary communication). Age Ageing 1 (1972) 74-80
2. Marcer D., and Hopkins S.M. The differential effects of meclofenoxate on memory loss in the elderly. Age Ageing 6 (1977) 123-131
3. al-Zuhair H., Abd el-Fattah A., and el-Sayed M.I. The effect of meclofenoxate with ginkgo biloba extract or zinc on lipid peroxide, some free radical scavengers and the cardiovascular system of aged rats. Pharmacol Res. 38 (1998) 65-72
4. Oliver J.E., and Restell M. Serial testing in assessing the effect of meclofenoxate on patients with memory defects. Br J Psychiatry 113 (1967) 219-222
5. Inada T., and Yagi G. Current topics in tardive dyskinesia in Japan. Psychiatry Clin Neurosci 49 (1995) 239-244
6. Nagy K., Nagy V., Bertoni-Freddari C., and Nagy I. Alterations of the synaptosomal membrane 'microviscosity' in the brain cortex of rats during aging and centrophenoxine treatment. Arch Gerontol Geriatr 2 (1983) 23-39
7. Wood P.L., and Péloquin A. Increases in choline levels in rat brain elicited by meclofenoxate. Neuropharmacology 21 (1982) 349-354
8. Liao Y., Wang R., and Tang X.C. Centrophenoxine improves chronic cerebral ischemia induced cognitive deficit and neuronal degeneration in rats. Acta Pharmacol Sin 12 (2004) 1590-1596
9. Riga D., and Riga S. Brain lipofuscinolysis and ceroidolysis-to be or not to be. Gerontology 41 Suppl 2 (1995) 271-281
10. Thomas L.H., Cross S., Barrett J., et al. Treatment of urinary incontinence after stroke in adults. Cochrane Database Syst Rev. (2008) CD004462
11. Predescu V., Riga D., Riga S., et al. Antagonic-stress. A new treatment in gerontopsychiatry and for a healthy productive life. Ann N Y Acad Sci 717 (1994) 315-331
12. Inada T., and Yagi G. Current topics in tardive dyskinesia in Japan. Psychiatry Clin Neurosci 49 (1995) 239-244
13. Tatsuhara T., and Tabuchi F. Analysis of meclofenoxate and its degradation products by high performance liquid chromatography. Chem Pharm Bull (Tokyo) 28 (1980) 779-782
14. Ohta N., Yotsuyanagi T., and Ikeda K. pH-dependent degradation and stabilization of meclofenoxate hydrochloride by human serum albumin. Chem Pharm Bull (Tokyo) 34 (1986) 2585-2590
15. Yoshioka S., Shibazaki T., and Ejima A. Stability of solid dosage forms, II. Hydrolysis of meclofenoxate hydrochloride in commercial tablets. Chem Pharm Bull (Tokyo) 31 (1983) 2513-2517
16. World Medical Association (WMA). Declaration of Helsinki. Ethical principles for medical research involving human subjects [WMA Web site]. http://www.wma.net/e/policy/b3.htm. Accessed August 16, 2006.
17. He L.Y., Xia H.P., Wu J.P., and Chen Z.N. Determination of meclofenoxate hydrochloride capsule by high performance liquid chromatography. Chin J Anal Lab 26 (2007) 74-76
18. US Food and Drug Administration. n vivo bioequivalence guidances. Pharmacopeial Forum 19 (1993) 6501-6508
19. US Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Guidance for Industry. Bioanalytical method validation [FDA Web site]. http://www.fda.gov/cder/guidance/4252fnl.htm. Accessed August 16, 2006.
20. Schuirmann D.J. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15 (1987) 657-680
21. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Statistical approaches to establishing bio-equivalence [FDA Web site]. http://www.fda.gov/cder/guidance/4252fnl.htm. Accessed August 16, 2006.
22. Statistical methods for average bioavailability and bioequivalence studies. In: Chow S.C., and Liu J.P. (Eds). Design and Analysis of Bioavailability and Bioequivalence Studies. 2nd ed (2000), Marcel Dekker, New York, NY 79-124
23. Power and sample size determination. In: Chow S.C., and Liu J.P. (Eds). Design and Analysis of Bioavailability and Bioequivalence Studies. 2nd ed (2000), Marcel Dekker, New York, NY 125-160